Loading...
•
Dec 31, 2021
Wave Life Sciences Q4 2021 Earnings Report
Wave Life Sciences reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $34.8 million in the fourth quarter of 2021, with revenue earned under the Takeda Collaboration at $1.8 million. Research and development expenses were $25.8 million, while general and administrative expenses were $12.1 million. The company's cash and cash equivalents totaled $150.6 million as of December 31, 2021, expected to fund operations into the second quarter of 2023.
PN chemistry was brought into the clinic with the initiation of three new clinical trials with next-generation RNA silencing and exon-skipping therapeutics.
Successful protein restoration expression was demonstrated with AIMers in preclinical in vivo models for the treatment of alpha-1 antitrypsin deficiency (AATD).
Data is expected in 2022 to inform the potential of novel oligonucleotides across tissues and modalities.
A first GalNAc-AIMer development candidate is expected to be selected in the third quarter of this year, advancing RNA base editing capabilities.
Forward Guidance
Wave Life Sciences expects that its existing cash and cash equivalents will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...